Akeso (9926.HK)

Executive Summary

Akeso is a leading Chinese biopharmaceutical company specializing in innovative oncology therapies, particularly immune checkpoint inhibitors and bispecific antibodies. The company has a robust pipeline with multiple assets in clinical development, including AK112 (PD-1/VEGF bispecific) in Phase 2 for non-small cell lung cancer (NSCLC), AK117 (anti-CD47) in Phase 2 for higher-risk myelodysplastic syndromes (MDS), and AK127 (TIGIT) in combination studies. Akeso's lead commercial product, AK105 (PD-1), is approved in China, providing a revenue base. The company's focus on next-generation immunotherapies positions it well in the competitive oncology landscape, though it faces risks from China's regulatory environment and global competition. Key near-term catalysts include data readouts from pivotal trials and potential regulatory submissions, which could drive significant value inflection.

Upcoming Catalysts (preview)

• Q3 2026AK112 Phase 2 data readout in first-line NSCLC75% success
• Q2 2026AK117 Phase 2 top-line results in higher-risk MDS60% success
• Q3 2026AK127 combination trial (with AK112) interim data50% success